Cite
Hohloch K, Zwick C, Ziepert M, et al. Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL. Springerplus. 2014;3:5doi: 10.1186/2193-1801-3-5.
Hohloch, K., Zwick, C., Ziepert, M., Hasenclever, D., Kaiser, U., Engert, A., Höffkes, H. G., Kroschinsky, F., Mesters, R., Feller, A. C., Löffler, M., Trümper, L., Pfreundschuh, M. (2014). Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL. SpringerPlus, 35. https://doi.org/10.1186/2193-1801-3-5
Hohloch, Karin, et al. "Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL." SpringerPlus vol. 3 (2014): 5. doi: https://doi.org/10.1186/2193-1801-3-5
Hohloch K, Zwick C, Ziepert M, Hasenclever D, Kaiser U, Engert A, Höffkes HG, Kroschinsky F, Mesters R, Feller AC, Löffler M, Trümper L, Pfreundschuh M. Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL. Springerplus. 2014 Jan 03;3:5. doi: 10.1186/2193-1801-3-5. eCollection 2014 Jan 03. PMID: 24455463; PMCID: PMC3890437.
Copy
Download .nbib